MedPath

Screening for Age-Related Skeletal Muscle Dysfunction

Conditions
Sarcopenia
Interventions
Radiation: DXA scanning
Radiation: CT imaging
Registration Number
NCT02277236
Lead Sponsor
Washington D.C. Veterans Affairs Medical Center
Brief Summary

This pilot study will aid the development of a sonographic screening method used to obtain proxy measures of LBM and estimates of muscle composition that relate to Intramuscular adipose tissue (IMAT), lipid metabolism, and insulin resistance. Typically, age-related muscle loss is not assessed in older adults until they began to show signs of trouble managing their own lives independently. In addition to the loss of independence that is typically seen with diminished muscle mass and function (sarcopenia), age-related changes in lean body mass can have negative effects on insulin sensitivity. The investigators central hypothesis is that the muscle characteristics derived from ultrasound (US) will be significantly associated with estimates of dual energy X-ray absorptiometry (DXA) LBM, CT scan measures of IMAT, estimates of insulin homeostasis, and serum levels of inflammatory cytokines.

Detailed Description

The primary goals of this project are to: 1) develop and validate a rapid, portable, cost-effective, screening method for sarcopenia using diagnostic ultrasound (US), and 2) determine if the US screening method provides viable estimates of intramuscular adipose tissue (IMAT) since muscle tissue age-related changes in muscle composition are associated with low muscle torque and metabolic dysfunction. The proposed US screening method may be used as a proxy measure of LBM and provide estimates of skeletal muscle composition that relate to IMAT, lipid metabolism, insulin homeostasis and inflammation - important factors that may impact impaired mobility and metabolic dysfunction in older African American Veterans.

Aim 1:

Determine the association between a proxy measure of LBM obtained via portable, diagnostic, musculoskeletal US and LBM as determined by dual energy X-ray absorptiometry (DXA).

The working hypothesis is that a 6-muscle model of LBM derived from US and DXA LBM values will exhibit a significant positive association and attain a coefficient of determination \> .80.

Aim 2:

Determine the association between US echointensity features and IMAT as determined by CT scan.

US echointensity values will be acquired from the rectus femoris and analyzed to determine the association with IMAT. The working hypothesis is that higher echointensity values measured with grayscale analysis will be negatively associated with the Hounsfield units obtained from the CT scan (p \< .05).

Aim 3:

Examine the association between US echointensity values and biologic factors that impair insulin sensitivity.

Excessive IMAT and intra-myocellular triglyceride levels result in increased levels of biologic factors such as inflammatory cytokines (TNF-α and IL-6), which may affect insulin sensitivity. The investigators hypothesis is that proxy measures of IMAT via echointensity values will be positively associated with biomarkers of inflammation and insulin homeostasis.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Male
Target Recruitment
30
Inclusion Criteria

You are eligible to participate if:

  1. You are registered to receive healthcare at the Washington DC VAMC through the Geriatrics Extended Care Service and/or Primary Care Service.

  2. You are a male.

  3. You are between the ages of 45 - 85 years.

  4. Must be able to stand comfortably for 10 minutes and walk a short distance (use of assistive devices are acceptable).

Exclusion Criteria

You are not eligible to participate if:

  1. You have uncontrolled hypertension.

  2. Body Mass Index (BMI) <18.5 or >32.5.

  3. Musculoskeletal conditions that would stop you from performing the physical assessment test.

  4. Muscle weakness due to neurological disease or injury (such as stroke or spinal cord injury).

  5. Moderate to severe sepsis (blood infection) or edema (such as swelling of a limb).

  6. Currently prescribed medications that affect glucose or insulin.

  7. Uncontrolled cardiovascular disease.

  8. Hospitalization over the last three months.

  9. Diagnosis of diabetes.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Younger VeteransDXA scanningMale Veterans, 45-64.9 years of age. (Exposures include DXA scanning and CT imaging.)
Young-Old VeteransCT imagingMale Veterans, 65-84.9 years of age. (Exposures include DXA scanning and CT imaging.)
Younger VeteransCT imagingMale Veterans, 45-64.9 years of age. (Exposures include DXA scanning and CT imaging.)
Young-Old VeteransDXA scanningMale Veterans, 65-84.9 years of age. (Exposures include DXA scanning and CT imaging.)
Primary Outcome Measures
NameTimeMethod
Sonographic Lean Body Mass1 day

US estimates of aggregate regional LBM (muscle thickness, cm), will be assessed using B-mode diagnostic US with a 13-6 MHz linear array transducer for morphology measures at 6 axial and appendicular sites. The following sites will be assessed: the midpoint of the upper trapezius, upper pectoralis major, lateral deltoid, brachioradialis, rectus femoris, and tibialis anterior.

Secondary Outcome Measures
NameTimeMethod
Intramuscular adipose tissue assessment1 day

Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. A single, unilateral 10mm axial image slice (120 kVp, 200 to 250 mA) of the thigh will be obtained at the midfemur region (corresponding to the ultrasound scanning site).

DXA lean body massAt time of assessment

Participants will undergo dual energy X-ray absorptiometry (DXA) scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total LBM, and body fat percentage (BF%).

Functional assessment1 day

A standardized timed sit-to-stand test will be conducted (5 repetitions); 6m walking speed (habitual and fast gait) will be recorded; the Physical Performance Test (PPT-7), a functional battery validated for use with older adults, will be used in this study to assess the activities of daily living of the participants.

Metabolic status1 day

A blood sample (60 cc) will be obtained after an 8-hour overnight fast: glucose and insulin levels will be assessed before and during a standard (75 g) 2 hour oral glucose tolerance test. Other laboratory values such as a standard lipid profile and selected cytokines (IL-6), will also be measured.

Physical activity questionnaire1 day

Participants will also complete the International Physical Activity Questionnaire (IPAQ) to obtain an estimate of their customary activity and formal exercise.

Strength assessment1 day

Grip strength will be assessed bilaterally; isokinetic knee extension/flexion torques will be obtained bilaterally using the Biodex System 4. Peak concentric torque (at 60º/s and 180º/s) will be obtained in a randomized fashion with subject positioning and stabilization per the Biodex Operations Manual.

Trial Locations

Locations (1)

Washington DC VA Medical Center

🇺🇸

Washington, District of Columbia, United States

© Copyright 2025. All Rights Reserved by MedPath